Here’s what you should know:
1. Janssen is conducting the phase 3 trial to create comparative data between the two CD treatment options.
2. Researchers plan to enroll approximately 350 patients into the study, which will take place at up to 100 worldwide sites.
3. The study will conclude in 2020.
4. The treatment phase of the study will take 52 weeks, with a follow-up phase of 76 weeks.
More articles on gastroenterology:
Joint replacement, spine ASC opens in Southern California
Dr. Paul Chin becomes 1st surgeon in Texas to use Catalyst Orthoscience device: 5 takeaways
5 organizations teaming up to tackle antibiotic resistance in outpatient space— 5 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
